 |
|
|
|
|
Table of Contents
- CHAPTER 1 EXECUTIVE SUMMARY
- Key findings
- Historical and forecast ethical sales performance
- Therapeutic strategy
- Launch and expiry outlook
- Externalization, geographic and molecule type strategies
- Externalization strategy
- Geographic strategy
- Molecule type strategy
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- CHAPTER 2 CORPORATE HISTORY
- Key findings
- Background
- Key corporate developments
- M&A history
- Astra AB
- Zeneca Group Plc
- Post-merger divestments
- Prilosec/Losec - the jewel in the crown
- Subsequent M&A strategy
- Abgenix
- Cambridge Antibody Technology (CAT)
- KuDOS Pharmaceuticals
- Arrow Therapeutics
- MedImmune
- M&A as driver of R&D restructuring
- CHAPTER 3 HISTORICAL PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate analysis, 2001-06
- Revenue and growth rate vs. peer set
- Product analysis, 2001-06
- Growth drivers
- Growth resistors
- Operating revenue and cost analysis, 2001-06
- Operating revenue/cost analysis
- CHAPTER 4 FORECAST PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate, 2006-12
- ICE (Iressa, Crestor and Exanta)
- Product analysis, 2006-12
- Growth drivers
- Symbicort
- Numax
- Crestor
- Recentin
- HPV vaccine royalties
- Growth resistors
- Betaloc
- Synagis
- Pulmicort
- Losec/Prilosec
- Therapy area analysis, 2006-12
- Respiratory
- Oncology
- Infectious disease
- Gastroenterology
- CV & hematology
- CNS
- Therapy area focus
- Launches and expiries analysis, 2006-12
- Launch portfolio
- Core portfolio
- Expiry portfolio
- Launch/core/expiry configuration
- Externalization analysis, 2006-12
- Geographic analysis, 2006-12
- Molecule type analysis, 2006-12
- CHAPTER 5 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Gastroenterology
- Nexium
- Overview
- Sales forecast
- Newsflow
- Losec/Prilosec
- Overview
- Sales forecast
- Newsflow
- CNS
- Seroquel
- Overview
- Sales forecast
- Newsflow
- Cardiovascular
- Crestor
- Overview
- Sales forecast
- Newsflow
- Betaloc (Toprol/Seloken)
- Overview
- Sales forecast
- Newsflow
- Respiratory
- Symbicort
- Overview
- Sales forecast
- Newsflow
- Pulmicort
- Overview
- Sales forecast
- Newsflow
- Oncology
- Arimidex
- Overview
- Sales forecast
- Newsflow
- Recentin
- Overview
- Sales forecast
- Newsflow
- HPV royalties
- Sales forecast
- News flow
- Significant revenue stream for AstraZeneca via MedImmune
- Infectious disease
- Synagis (palivizumab)
- Overview
- Sales forecast
- News flow
- Competitive landscape
- Numax (motavizumab)
- Overview
- Sales forecast
- News flow
- Competitive landscape
- R&D pipeline
- CHAPTER 6 APPENDIX
- IMS vs. company-reported data reconciliation
- Abbreviations
- List of Tables
- Table 1: Peer set overview
- Table 2: Operating revenue/cost analysis ($m), 2001-06
- Table 3: Operating cost ratio analysis (% of total revenues), 2001-06
- Table 4: Product portfolio overview, sales ($m), 2006-12
- Table 5: Therapy area overview, sales ($m), 2006-12
- Table 6: Launch portfolio overview, sales ($m), 2006-12
- Table 7: Core portfolio overview, sales ($m), 2006-12
- Table 8: Expiry portfolio overview, sales ($m), 2006-12
- Table 9: Externally developed portfolio ($m), 2006-12
- Table 10: Molecule type overview, sales ($m), 2006-12
- Table 11: Key products overview
- Table 12: Nexium: overview
- Table 13: Nexium: sales forecast ($m), 2006-12
- Table 14: Nexium: news flow
- Table 15: Losec/Prilosec: overview
- Table 16: Losec/Prilosec: sales forecast ($m), 2006-12
- Table 17: Losec/Prilosec: news flow
- Table 18: Seroquel: overview
- Table 19: Seroquel: sales forecast ($m), 2006-12
- Table 20: Seroquel: news flow
- Table 21: Crestor: overview
- Table 22: Crestor: sales forecast ($m), 2006-12
- Table 23: Crestor: news flow
- Table 24: Betaloc (Toprol/Seloken): overview
- Table 25: Betaloc (Toprol/Seloken): sales forecast ($m), 2006-12
- Table 26: Betaloc (Toprol/Seloken): news flow
- Table 27: Symbicort: overview
- Table 28: Symbicort: sales forecast ($m), 2006-12
- Table 29: Symbicort: news flow
- Table 30: Pulmicort: overview
- Table 31: Pulmicort: sales forecast ($m), 2006-12
- Table 32: Pulmicort: news flow
- Table 33: Arimidex: overview
- Table 34: Arimidex: sales forecast ($m), 2006-12
- Table 35: Arimidex: news flow
- Table 36: Recentin: overview
- Table 37: Recentin: sales forecast ($m), 2006-12
- Table 38: Recentin: news flow
- Table 39: HPV royalty revenues sales forecast ($m), 2006-12
- Table 40: HPV royalties: news flow
- Table 41: Synagis: overview
- Table 42: Synagis sales forecast ($m), 2006-12
- Table 43: Synagis: news flow
- Table 44: Numax: overview
- Table 45: Numax sales forecast ($m), 2006-12
- Table 46: Numax: news flow
- Table 47: AstraZeneca' s R&D pipeline (Phase I-registration)
- List of Figures
- Figure 1: Historical and forecast ethical sales performance (% CAGR),
AstraZeneca and Big Pharma peer set
- Figure 2: AstraZeneca' s Therapeutic focus vs. Big Pharma peer set (%),
2006
- Figure 3: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), AstraZeneca
- Figure 4: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set
- Figure 5: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2006
- Figure 6: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2012
- Figure 7: SWOT analysis of AstraZeneca
- Figure 8: M&A/divestment history AstraZeneca
- Figure 9: Revenue & growth rate (ethical sales) ($m), 2001-06
- Figure 10: Ethical revenue ($m) and growth rate (%) vs. peer set,
2001-06
- Figure 11: Growth drivers/resistor products of historical revenue
performance ($m), 2001-06
- Figure 12: Operating revenue/cost analysis ($m), 2001-06
- Figure 13: Operating cost ratio analysis (% of total revenues), 2001-06
- Figure 14: Ethical revenue ($m) and growth rate (%), 2006-12
- Figure 15: Top five products by sales ($m), 2006
- Figure 16: Top five products by sales ($m), 2012
- Figure 17: Growth drivers and resistors by product, 2006-12
- Figure 18: Key strategic products, sales ($m), 2006-12
- Figure 19: Ethical sales by therapy area ($m), 2006-12
- Figure 20: Growth drivers and resistors by therapy area ($m), 2006-12
- Figure 21: Ethical sales by therapy area (%), 2006-12
- Figure 22: Therapy area focus compared with peer set (% total ethical
sales), 2006
- Figure 23: Therapy area focus compared with peer set (% total ethical
sales), 2012
- Figure 24: Launch schedule, sales ($m), 2006-12
- Figure 25: Core products sales growth ($m), 2006-12
- Figure 26: Expiry schedule, sales ($m), 2006-12
- Figure 27: Launch, core and expiry, sales ($m), 2006-12
- Figure 28: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), AstraZeneca
- Figure 29: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set
- Figure 30: Externalization dependency, sales ($m), 2006-12
- Figure 31: Growth drivers and resistors, externally vs. internally
discovered products, sales ($m), 2006-12
- Figure 32: Externalization dependency vs. peer set, % total sales, 2006
- Figure 33: Externalization dependency vs. peer set, % total sales, 2012
- Figure 34: Geographical sales breakdown ($m), 2006-12
- Figure 35: Growth drivers and resistors by geography, sales ($m),
2006-12
- Figure 36: US dependency vs. peer set, % total sales, 2006
- Figure 37: US dependency vs. peer set, % total sales, 2012
- Figure 38: Growth drivers and resistors by molecule type, sales ($m),
2006-12
- Figure 39: Molecule type sales breakdown ($m), 2006-12
- Figure 40: Biologics dependency vs. peer set, % total sales, 2006
- Figure 41: Biologics dependency vs. peer set, % total sales, 2012
- Figure 42: IMS vs. company-reported ethical sales discrepancy ($m),
2006
- Figure 43: IMS vs. company-reported ethical sales forecast growth
rates (%), 2006-12
|
|
|
|
|
|
View Cart
